Informations générales (source: ClinicalTrials.gov)
Leukemia Cell Cultures for Research of New Anti-cancer Therapies
Interventional
N/A
University Hospital, Strasbourg, France (Voir sur ClinicalTrials)
juillet 2009
29 juin 2024
The main objective of this project is not only a better understanding of the human
leukemic disease but also to find new anti-leukemic or improve existing ones. This study
has, the following aims:
- To analyze the genetic and epigenetic regulation of the retinoic acid induced
cascade which leads to the expression of TRAIL in blood cells of patients with acute
leukemia. This study will be complemented by the analysis of global gene expression
(DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation
experiences.
- To determine the efficiency of inhibitors of enzymes responsible for the
modification of chromatin (existing and new developments within the European
consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and
/ or apoptosis of leukemic blasts.
- To explore Ikaros genic and functional abnormalities (genomic deletions, mutations,
abnormal transcripts and proteins) in acute leukemia. The aim is to determine if
these abnormalities may play a prognosis role.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Service d'Hématologie et d'Oncologie - 67098 - Strasbourg - France | Raoul Herbrecht, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Service de Pédiaterie - Hôpital de Hautepierre - 67098 - Strasbourg - France | Patrick Lutz, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients with suspected de novo or secondary or relapsed acute leukemia, requiring
complementary blood test and bone marrow analysis
- Patients older or equal than 28 days
- Informed consent signed
- Patients with suspected de novo or secondary or relapsed acute leukemia, requiring
complementary blood test and bone marrow analysis
- Patients older or equal than 28 days
- Informed consent signed
- Pregnancy
- Breastfeeding